Kodiak Sciences IncNASDAQ:KOD
- LAST PRICE6.4000
- TODAY'S CHANGE (%)-0.0300 (-0.4666%)
- Bid / Lots6.4000/ 1
- Ask / Lots6.4400/ 2
- Open / Previous Close6.4300 / 6.4300
- Day Range
- 52 Week Range
- Volume4,943
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 15, 2024
DJ Kodiak Sciences Is Maintained at Underweight by Barclays, from 10:01AM ET on Friday Nov 15, 2024 by Dow Jones
10:01AM ET on Friday Nov 15, 2024 by Dow JonesDJ Kodiak Sciences Price Target Maintained With a $3.00/Share by HC Wainwright & Co., from 6:31AM ET on Friday Nov 15, 2024 by Dow Jones
6:31AM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones*DJ Kodiak Sciences 3Q Loss/Shr 84c >KOD, from 4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
4:01PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 11, 2024
Kodiak Sciences to Participate in Upcoming Investor Conferences, from 6:15AM ET on Monday Nov 11, 2024 by Dow Jones
6:15AM ET on Monday Nov 11, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kodiak Sciences Inc | 325.7M | -1.8x | --- |
Jasper Therapeutics Inc | 330.8M | -4.8x | --- |
Design Therapeutics Inc | 318.2M | -6.6x | --- |
enGene Holdings Inc | 339.6M | -1.7x | --- |
Lexicon Pharmaceuticals Inc | 312.1M | -1.1x | --- |
Compass Pathways PLC | 301.7M | -2.1x | --- |
Company Information
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Contact Information
- Headquarters
- 1200 PAGE MILL RDPALO ALTO, CA, United States 94304
- Phone
- 650-281-0850
- Fax
- 302-636-5454
Executives
- Chairman of the Board, Chief Executive Officer, Co-Founder
- Victor Perlroth
- Chief Financial Officer, Executive Vice President, Secretary
- John Borgeson
- Independent Director
- Robert Profusek
- Independent Director
- Felix Baker
- Independent Director
- Charles Bancroft
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $325.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 52.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.34 |
EPS | $-3.65 |
Book Value | $5.06 |
P/E Ratio | -1.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
